NASDAQ:QNTM Quantum Biopharma Q1 2025 Earnings Results & Report $2.71 +0.05 (+1.88%) Closing price 04:00 PM EasternExtended Trading$2.66 -0.05 (-1.85%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Quantum Biopharma missed analyst earnings expectations but beat on revenue in its Q1 2025 results, released May 14, 2025. The company reported EPS of -$1.41 versus the -$0.37 consensus estimate, while revenue of $2.09 million topped the $2.09 million estimate by $0.00 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 14, 2025TimeAfter Market Closes Quantum Biopharma EPS ResultsActual EPS-$1.41Consensus EPS -$0.37Beat/MissMissed by -$1.04One Year Ago EPSN/AEPS Beat Rate0 of last 8 quartersQuantum Biopharma Revenue ResultsActual Revenue$2.09 millionExpected Revenue$2.09 millionBeat/MissBeat by +$2.00 thousandYoY Revenue GrowthN/AUpcoming EarningsQuantum Biopharma's next earnings date is estimated for Friday, November 6, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Quantum Biopharma Q1 2025 Earnings FAQ Did Quantum Biopharma beat earnings estimates for Q1 2025? Quantum Biopharma (NASDAQ:QNTM) reported earnings of -$1.41 per share for Q1 2025, missing the consensus estimate of -$0.37. The report was announced on Wednesday, May 14, 2025. What was Quantum Biopharma's revenue for Q1 2025? Quantum Biopharma reported revenue of $2.09 million for Q1 2025, against a consensus estimate of $2.09 million. When is Quantum Biopharma's next earnings date? Quantum Biopharma's next earnings date is estimated for Friday, November 6, 2026. MarketBeat tracks confirmed and estimated earnings dates for Quantum Biopharma on the company's earnings history page. Quantum Biopharma Earnings HeadlinesQuantum BioPharma Ltd. (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 TrialOctober 12 at 1:31 PM | insidermonkey.comQuantum BioPharma (NASDAQ: QNTM) gets consolidation in market-manipulation suitOctober 11, 2026 | americanbankingnews.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.October 15 at 1:00 AM | Banyan Hill Publishing (Ad)World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market ...October 8, 2026 | markets.businessinsider.comWorld Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma SharesOctober 8, 2026 | globenewswire.comQuantum BioPharma (NASDAQ: QNTM) Enlists Thermo Fisher’s Clinical Research Business to Launch Phase 2 Lucid-MS TrialOctober 8, 2026 | usatoday.comSee More Quantum Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Quantum Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quantum Biopharma and other key companies, straight to your email. Email Address About Quantum BiopharmaQuantum Biopharma (NASDAQ:QNTM) (NASDAQ:QNTM) is a biotechnology company focused on developing treatments for neurodegenerative and inflammatory disorders, as well as alcohol and substance-use disorders. The company’s research programs are intended to address conditions for which existing treatment options may be limited. Its lead development program is Lucid-MS, an investigational small-molecule therapy designed to protect or restore myelin, the insulating material surrounding nerve fibers. Quantum BioPharma has identified multiple sclerosis as a potential application for the program and continues to evaluate its broader potential in neurodegenerative diseases. The company also has research activities related to alcohol-use disorder and other central nervous system conditions. Quantum BioPharma was formerly known as FSD Pharma Inc. and adopted its current name as part of a corporate rebranding. The company is based in Canada and conducts its business through research and development activities and related subsidiaries, including Lucid Psycheceuticals. Zeeshan Saeed serves as the company’s chief executive officer and president.View Quantum Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
